Collegium Pharmaceutical, Inc. - Common Stock COLL announces its next round of earnings Wednesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Sell-side analysts are expecting Collegium's loss per share to be near 57 cents on sales of $9.9 million.
Collegium's loss in the same period a year ago was $1.02. Quarterly sales came in at $1.3 million. If the company were to report inline earnings when it publishes results Wednesday, quarterly profit would be down 44.12 percent. Revenue would be have grown 658.25 percent from the same quarter last year.
Collegium's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.74 | -0.83 | -0.98 | -1.07 |
| EPS Actual | -0.45 | -0.72 | -0.79 | -1.02 |
Stock Performance
Over the last 52-week period, shares are up 74.47 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.
Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. The average rating by analysts on Collegium stock is a Buy. The strength of this rating has risen over the past 90 days.
Conference Call
Collegium Pharmaceutical's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
